Related references
Note: Only part of the references are listed.Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
Tao Xia et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
Yuichiro Doki et al.
CANCER MEDICINE (2022)
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
Do-Youn Oh et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma
Youpei Lin et al.
CANCER DISCOVERY (2022)
The Tumor Microenvironment in Cholangiocarcinoma Progression
Luca Fabris et al.
HEPATOLOGY (2021)
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
Wei Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Alice Boileve et al.
EUROPEAN JOURNAL OF CANCER (2021)
Immunotherapies in clinical development for biliary tract cancer
Arndt Vogel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial
Zhou Jun et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
Zhengjun Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo et al.
CANCERS (2021)
The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
Massimiliano Salati et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
ONCOLOGIST (2021)
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
Kamonlapat Supimon et al.
SCIENTIFIC REPORTS (2021)
The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
Dongxu Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
Do-Youn Oh et al.
ANNALS OF ONCOLOGY (2021)
A pilot study of the combination of checkpoint inhibition with ablation in subjects with biliary tract cancer.
Rebecca Wetzel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
Mark Yarchoan et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Hepatobiliary Cancers, Version 2.2021
Al B. Benson III et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts
Takahiro Yamanaka et al.
BRITISH JOURNAL OF CANCER (2020)
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Sylvie Job et al.
HEPATOLOGY (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Toshihiko Doi et al.
ONCOLOGIST (2020)
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
Oliver Klein et al.
JAMA ONCOLOGY (2020)
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo et al.
ESMO OPEN (2020)
LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Z. Lwin et al.
ANNALS OF ONCOLOGY (2020)
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
Mairead G. McNamara et al.
CANCER TREATMENT REVIEWS (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
Reham Abdel-Wahab et al.
SCIENTIFIC REPORTS (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
Julius Strauss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
Alessandro Rizzo et al.
CANCER CONTROL (2020)
Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging
Domenico Alvaro et al.
DIGESTIVE AND LIVER DISEASE (2020)
A framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai et al.
NATURE REVIEWS CANCER (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
Lorenza Rimassa et al.
JOURNAL OF AUTOIMMUNITY (2019)
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Weiqiang Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications
Hsing-Ju Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
1272PLenvatinib plus PD-1 blockade in advanced bile tract carcinoma
J Lin et al.
ANNALS OF ONCOLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Immunobiology of cholangiocarcinoma
Emilien Loeuillard et al.
JHEP REPORTS (2019)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma
Massimiliano Cadamuro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model
In Hye Jung et al.
IN VIVO (2018)
Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
Angela Lamarca et al.
CANCER TREATMENT REVIEWS (2018)
1160PPhase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors
A El-Khoeuiry et al.
ANNALS OF ONCOLOGY (2018)
660PSafety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies
S J Klempner et al.
ANNALS OF ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
Wouter W. van Willigen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
Entinostat: a promising treatment option for patients with advanced breast cancer
Roisin M. Connolly et al.
FUTURE ONCOLOGY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne et al.
ONCOTARGET (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
Takahisa Shirahama et al.
CANCER SCIENCE (2017)
Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma
Guohe Lin et al.
ONCOTARGET (2016)
Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma
Stephanie Lacotte et al.
OncoImmunology (2016)
Downregulation of FOXP3 inhibits invasion and immune escape in cholangiocarcinoma
Chao Ma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
B. Goeppert et al.
BRITISH JOURNAL OF CANCER (2013)
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Masanori Kobayashi et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Re(de)fining the dendritic cell lineage
Ansuman T. Satpathy et al.
NATURE IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
Miho Kaida et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Minu K. Srivastava et al.
CANCER RESEARCH (2010)
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Ilaria Marigo et al.
IMMUNITY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-Activated T cells and dendritic cells after surgery: Report of a case
Ryota Higuchi et al.
SURGERY TODAY (2006)
Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma
S Takagi et al.
HUMAN PATHOLOGY (2004)
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism
A Mazzoni et al.
JOURNAL OF IMMUNOLOGY (2002)
Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
H Jonuleit et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
